When he arrived at Sanofi, "I thought the solution would be simple," Zerhouni said at a recent R&D press event ...
While at the NIH, Zerhouni witnessed a lot of progress in basic science that had implications for human health. But those findings weren't being translated because clinician-scientists weren't receiving the right training, he said.
At pharma companies, most R&D scientists are too isolated — they talk primarily to those within their own company — and the experimental therapies that companies are developing are created without enough communication with the doctors who actually treat patients.
There needs to be a "re-do" in pharma R&D, Zerhouni said.